欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (10): 1158-1161.

• 药物治疗学 • 上一篇    下一篇

左炔诺孕酮宫内缓释系统治疗子宫腺肌症患者的疗效分析

茅晶晶,郑孟女,胡炳真   

  1. 慈溪市人民医院妇产科,慈溪 315300,浙江
  • 收稿日期:2017-04-11 修回日期:2017-05-03 出版日期:2017-10-26 发布日期:2017-11-13
  • 作者简介:茅晶晶,女,本科,主治医师,主要从事妇产科研究。 Tel:13456827380 E-mail:m5219952466@163.com
  • 基金资助:

    宁波市科技局项目(2012C50028)

Curative effect of LNG-IUS in the treatment of adenomyosis

MAO Jingjing, ZHENG Mengnv, HU Bingzhen   

  1. Department of Obstetrics and Gynecology, Cixi People's Hospital, Cixi 315300, Zhejiang, China
  • Received:2017-04-11 Revised:2017-05-03 Online:2017-10-26 Published:2017-11-13

摘要:

目的:  研究左炔诺孕酮宫内缓释系统(levonorgestrelreleasing intrauterine system,LNG-IUS)对子宫腺肌症合并中重度痛经患者的影响。方法: 在本院接受治疗的子宫腺肌病合并中重度痛经患者160例,用随机数表法分为对照组和试验组,各80例。对照组患者口服米非司酮片12.5 mg,每日一次,口服,连续服用6个月。试验组患者在月经第5~7天放置LNG-IUS,含52 mg左炔诺孕酮,缓释速度为20 μg/d。比较2组患者的痛经评分、Pictorial Blood Loss Assessment Chart (PBAC)评分、子宫情况及血红蛋白、糖类抗原(CA125)水平。结果:治疗前两组患者的痛经评分相近(P>0.05),试验组患者治疗1个月后、3个月后及6个月后的痛经评分分别为(1.71±0.46)分、(1.03±0.27)分和(0.68±0.47)分,对照组分别为(2.06±0.51)分、(1.43±0.50)分和(1.08±0.35)分,差异有统计学意义(P<0.05)。治疗前两组患者的PBAC评分相近(P>0.05),试验组患者治疗1个月后、3个月后及6个月后的PBAC评分分别为(108.36±23.10)分、(71.83±19.51)分和(42.98±16.19)分,对照组患者分别为(131.96±26.43)分、(95.60±22.56)分和(69.76±17.71)分,差异有统计学意义(P<0.05)。治疗前两组患者的子宫内膜、子宫体积及血红蛋白、CA125水平相近(P>0.05),治疗6个月后,试验组患者的子宫内膜、子宫体积、CA125水平和血红蛋白水平分别为(4.72±1.24)mm、(134.53±22.09)cm3、(23.85±11.31)U/mL和(127.04±12.90)g/L,对照组分别为(6.55±2.95)mm、(158.45±26.96)cm3、(36.35±15.19)U/mL和(108.63±12.01)g/L,差异有统计学意义(P<0.05)。 结论: LNG-IUS可以明显减轻子宫腺肌症合并中重度痛经患者的疼痛程度,减少月经量,控制子宫内膜增生,降低CA125水平,提高血红蛋白水平,值得在临床推广应用。

关键词: 左炔诺孕酮宫内缓释系统, 米非司酮, 子宫腺肌病, 中重度痛经

Abstract:

AIM: To research the effect of LNG-IUS on adenomyosis with moderate to severe dysmenorrhea patients. METHODS: 160 cases of adenomyosis with moderate to severe dysmenorrhea patients treated in our hospital were selected, they were divided into control group and treatment group randomly, each group had 80 cases.Patients in the control group were treated with Mifepristone Tablets 12.5 mg, once a day, orally for 6 months. Patients in the treatment group were placed LNG-IUS in menstrual 5-7 d, 52 mg containing levonorgestrel, release rate was 20 g/d. Compared with the dysmenorrhea score, PBAC score, the situation of the uterus and hemoglobin, CA125 levels between the two groups.RESULTS:The score of the two groups of patients before treatment of dysmenorrhea was similar (P>0.05), 1 months after the treatment in the test group, after 3 months and 6 months after the dysmenorrhea scores were (1.71±0.46), (1.03±0.27) and (0.68±0.47), control group were respectively (2.06±0.51), (1.43±0.50) and (1.08±0.35), the difference had statistical significance (P<0.05). Two groups of patients before treatment PBAC score were similar (P>0.05).The PBAC score of 1 months,3 months and 6 months after the treatment in the test group were (108.36±23.10), (71.83±19.51) and (42.98±16.19), those of patients in the control group were (131.96±26.43), (95.60±22.56) and (69.76±17.71),respectively.The difference had statistical significance (P<0.05). Two groups of patients before treatment of endometrium, uterine volume and hemoglobin, close to the level of CA125 (P>0.05), after 6 months of treatment, the test group of patients with endometrial and uterine volume, the level of CA125 and hemoglobin levels were (4.72±1.24) mm, (134.53±22.09) cm3, (23.85±11.31) U/mL and (127.04±12.90) g/L, the control group were respectively (6.55±2.95) mm, (158.45±26.96) cm3, (36.35±15.19) U/mL and (108.63±12.01) g/L, the difference had statistical significance (P<0.05). CONCLUSION: LNG-IUS can significantly reduce the pain of adenomyosis with severe dysmenorrhea patients, reduce menstrual flow, control endometrial hyperplasia, reduce the level of CA125, improve the level of hemoglobin, it is worthy of clinical application.

Key words: levonorgestrel intrauterine system, mifepristone, adenomyosis, severe dysmenorrhea

中图分类号: